Dose-finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer

C. Sessa, O. Pagani, G. Martinelli, T. Cerny, J. De Jong, A. Goldhirsch, M. Zimatore, F. Cavalli

Research output: Contribution to journalArticlepeer-review


The primary aim of this study was to define the maximum tolerated doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given by 3-hour infusion and cyclophosphamide given by intravenous bolus every 3 weeks in patients with breast cancer. Patients had received a maximum of one prior chemotherapy for advanced disease. The maximum tolerated dose of the combination was also determined with granulocyte colony-stimulating factor (G-CSF) support. The 80 women who took part in this study received 347 fully evaluable courses of therapy. Starting doses were paclitaxel 135 mg/m2 and cyclophosphamide 750 mg/m2; G-CSF support (5 μg/kg subcutaneously) was added at the subsequent cycle if specific dose-limiting toxicities had occurred during the previous cycle. Febrile neutropenia and severe thrombocytopenia defined the maximum tolerated doses as paclitaxel 200 mg/m2 and cyclophosphamide 2,000 mg/m2, with or without G-CSF support, in patients with or without a prior chemotherapy. Recommended doses were paclitaxel 200 mg/m2 and cyclophosphamide 1,750 mg/m2 in these two groups of patients. The overall response rate was 25% among patients who had received prior therapy for metastatic disease and 50% in patients who had not been previously treated. Complete remissions were reported in 9% of patients, but only among those who were previously untreated.

Original languageEnglish
JournalSeminars in Oncology
Issue number5 SUPPL. 17
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Dose-finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer'. Together they form a unique fingerprint.

Cite this